Sparsentan in immunoglobulin A nephropathy: a profile of its use

<p>  </p> <div><strong>Funding</strong> The preparation of this review was not supported by any external funding.</div> <div><strong>  </strong></div><strong> <p><strong>Authorship and conflict of interest</strong> Young-A Heo, a salaried employee of Adis International Ltd/Springer Nature and an editor of <em>Drugs & Therapy Perspectives, </em>and Connie Kang, a salaried employee of Adis International Ltd./Springer Nature, were<em> </em>not involved in any publishing decisions for the manuscript and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.</p> <div><strong>Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability not applicable</strong></div><strong> <p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews" target="_blank">here</a></p> <p><br></p> <p><br></p> <p><strong>Abstract</strong></p> <p>Sparsentan (FILSPARI^®), an oral, dual endothelin and angiotensin receptor antagonist, is an emerging new treatment option for patients with immunoglobulin A (IgA) nephropathy. Sparsentan received accelerated approval in the USA for the treatment of adults with IgA nephropathy who are at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UP/C) ≥ 1.5 g/g. In the ongoing phase 3 PROTECT trial in adults with IgA nephropathy, sparsentan was associated with favourable antiproteinuric effects, which were maintained over 110 weeks of treatment. The change in UP/C from baseline at week 36 was significantly greater with sparsentan than with irbesartan, an angiotensin receptor blocker. Early results from the 110-week final analysis of PROTECT also suggested that sparsentan may provide long-term benefits in preserving kidney function in patients with IgA nephropathy. Final analyses from the PROTECT trial, including its open-label extension period, are awaited with interest. Sparsentan was generally well tolerated, with its tolerability profile being similar to that of irbesartan. The most common treatment-emergent adverse events with sparsentan included peripheral oedema, hypotension, dizziness and hyperkalaemia. Longer-term data revealed no new safety signals. </p> <p>  </p> <p>© Springer Nature Switzerland AG 2024</p> <p><br></p></strong></strong>